BSBenedykt Szczepankiewicz

Benedykt Szczepankiewicz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benedykt Szczepankiewicz has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-Time Biomarkers of Liver Graft Quality in Hypothermic Oxygenated Machine Perfusion

    by Andriy Zhylko, Marcin Morawski, Paweł Rykowski, Maciej Krasnodębski, Anya Wyporski, Jan Borkowski, Dmytro Zhylko, Konrad Kobryń, Rafał Stankiewicz, Jan Stypułkowski, et al.

    Background: Hypothermic oxygenated machine perfusion has emerged as a strategy to alleviate ischemic-reperfusion injury in liver grafts. Nevertheless, there is limited data on the effectiveness of hypothermic liver perfusion in evaluating organ quality. This study aimed to introduce a readily accessible real-time predictive biomarker measured in machine perfusate for post-transplant liver graft function. Methods: The study evaluated perfusate analytes over a 90-day postoperative period in 26 patients randomly assigned to receive a liver graft following dual hypothermic machine perfusion in a prospective randomized controlled trial. Machine perfusion was consistently conducted end-ischemically for at least 120 min, with real-time perfusate assessment at 30-min intervals. Graft functionality was assessed using established metrics, including Early Allograft Dysfunction (EAD). Results: Perfusate lactate concentration after 120 min of machine perfusion demonstrated significant predictive value for EAD (AUC ROC: 0.841, p = 0.009). Additionally, it correlated with post-transplant peak transaminase levels and extended hospital stays. Subgroup analysis revealed significantly higher lactate accumulation in livers with post-transplant EAD. Conclusions: Liver graft quality can be effectively assessed during hypothermic machine perfusion using simple perfusate lactate measurements. The reliability and accessibility of this evaluation support its potential integration into diverse transplant centers.


  • Open Access

    Prognostic factors for hepatocellular carcinoma recurrence after liver transplantation or resection – single-center experience

    by Maciej Gryziak, Rafał Stec, Krzysztof Woźniak, Benedykt Szczepankiewicz, Maciej KrasnodęBski, Michał Grąt, Leszek Kraj


  • Open Access

    Routine end-ischemic hypothermic machine perfusion in liver transplantation from donors after brain death: results of 2-year follow-up of a randomized controlled trial

    by Marcin Morawski, Andriy Zhylko, Paweł Rykowski, Maciej Krasnodębski, Wacław Hołówko, Zbigniew Lewandowski, Magdalena Mielczarek-Puta, Marta Struga, Benedykt Szczepankiewicz, Barbara Górnicka, et al.

    Background: Data on routine hypothermic machine perfusion of livers procured from donors after brain death (DBD) are scarce, and the benefits of the method have only been demonstrated in extended criteria grafts. This study aimed to assess if end-ischemic dual hypothermic oxygenated machine perfusion (dHOPE) is superior to static cold storage (SCS) in preservation of livers procured from DBD donors with respect to long-term outcomes. Existing data on short-term outcomes favours dHOPE in patients receiving high-risk grafts. Methods: This prospective randomized controlled trial included 104 recipients of DBD livers randomly assigned to SCS arm (78 patients) and the dHOPE arm (26 patients). Endpoints of interest were the occurrence of biliary complications (biliary fistula, anastomotic, and nonanastomotic strictures) and overall patient and graft survival (GS) during the 2-year follow-up. Results: A total of 36 patients developed biliary complications (at least one event) – six events in dHOPE arm and 30 in SCS arm. There was no significant difference in biliary complications between groups (23.7 vs. 43.4%, P=0.11). No differences were found significant with respect to anastomotic (19.9 vs. 33.7%, P=0.20) and nonanastomotic strictures (0 vs. 11.1%, P=0.10) as well as biliary fistulas (11.7 vs. 12.2%, P=0.93). Survival analysis did not show significantly different results in the study population – overall survival: 92.3% in dHOPE and 83.9% in SCS (P=0.35), and GS: 92.3 and 81.4% (P=0.23), respectively. However, a significant difference in GS was noted in recipients of high-risk grafts – 100% in dHOPE and 73.1% in SCS, respectively (P=0.038). Conclusions: The long-term outcome data suggest that the routine use of dHOPE may be beneficial for recipients of high-risk grafts from DBD donors. The present study does not provide any evidence for the benefits of dHOPE in low-risk grafts.